Focused update of ESC Heart Failure Guidelines published today
2023-08-25
(Press-News.org) Amsterdam, Netherlands – 25 Aug 2023: A focused update of the European Society of Cardiology (ESC) Heart Failure Guidelines is published online today in European Heart Journal following the results of major new trials that should change the management of patients with heart failure.1
“Heart failure is a fast-moving area of research and exciting new trials are expanding the treatment options for patients,” said Guidelines task force chairperson Professor Theresa McDonagh of King’s College Hospital, London, UK. “This focused update incorporates the latest evidence-based treatments into state-of-the-art management recommendations with the aim of improving the outcome of patients with heart failure.”
Chronic heart failure is a condition in which the heart can no longer pump blood around the body as well as it should. It typically occurs because the heart has become too weak or stiff. Ejection fraction, meaning the proportion of blood that is ejected when the heart pumps, is a measure of cardiac function that is used to categorise the types of chronic heart failure. Acute heart failure is life-threatening and requires urgent treatment; it can be the first manifestation of heart failure but is more often due to an acute deterioration of chronic heart failure.
Guidelines task force chairperson Professor Marco Metra of the University of Brescia, Italy said: “In 2021, the ESC published Guidelines for the diagnosis and treatment of acute and chronic heart failure.2 Since then, more than 10 randomised controlled trials have been released that should change patient management ahead of the next scheduled full guideline, necessitating a focused update. New recommendations are provided in three areas: chronic heart failure, acute heart failure, and comorbidities.”
Regarding chronic heart failure, in the 2021 Guidelines there were no recommendations on the use of sodium–glucose co-transporter 2 (SGLT2) inhibitors in patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) as no trials had been conducted in these groups. Since then, the EMPEROR-Preserved trial and the DELIVER trial were conducted with the SGLT2 inhibitors empagliflozin and dapagliflozin, respectively. The focused update recommends an SGLT2 inhibitor (dapagliflozin or empagliflozin) in patients with HFmrEF and HFpEF to reduce the risk of heart failure hospitalisation or cardiovascular death.
The 2021 Guidelines emphasised the importance of pre-discharge and early post-discharge assessment in patients admitted to hospital for an episode of acute heart failure. Following that, the STRONG-HF trial showed the safety and efficacy of starting oral medical therapy, and achieving optimal doses, before hospital discharge and in early follow-up visits post-discharge. Based on these results, the focused update recommends an intensive strategy of initiation and rapid up-titration of evidence-based treatment before discharge and during frequent and careful follow-up visits in the first six weeks after hospitalisation for heart failure to reduce readmission and mortality.
The focused update stresses that during follow-up appointments, particular attention should be paid to symptoms and signs of congestion, blood pressure, heart rate, NT-proBNP plasma concentrations, potassium concentrations, and estimated glomerular filtration rate (eGFR, an indicator of kidney function). These factors are linked with prognosis and can signal the need for further changes in treatment.
Turning to comorbidities, the focused update provides two new recommendations for the prevention of heart failure in patients with chronic kidney disease and type 2 diabetes. Based on the results of the DAPA-CKD and EMPA-KIDNEY trials, and a meta-analysis of four trials, the focused update recommends SGLT2 inhibitors for patients with chronic kidney disease and type 2 diabetes to reduce the risk of heart failure hospitalisation or cardiovascular death. The second recommendation follows the FIDELIO-DKD and FIGARO-DKD trials and a pooled analysis of the two studies. The focused update recommends the MRA finerenone for patients with type 2 diabetes mellitus and chronic kidney disease to reduce the risk of heart failure hospitalisation.
The second comorbidity addressed in the focused update is iron deficiency. The results of new trials including IRONMAN, plus meta-analyses, have led to new recommendations in the focused update. Intravenous iron supplementation is now recommended in iron deficient patients with heart failure with reduced ejection fraction (HFrEF) or HFmrEF to improve symptoms and quality of life, and should be considered to reduce the risk of heart failure hospitalisation.
ENDS
Notes to editors
Authors: ESC Press Office
Mobile: +336 61 40 18 84
Email: press@escardio.org
The hashtag for ESC Congress 2023 is #ESCCongress.
Follow us on Twitter @ESCardioNews
Funding: None.
Disclosures: The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website www.escardio.org/guidelines.
References and notes
12023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023. https://doi.org/10.1093/eurheartj/10.1093/eurheartj/ehad195
22021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42:3599-3726.
About ESC Congress 2023
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Amsterdam and online – from 25 to 28 August. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-08-25
“One can expect that artificial intelligence (AI) will play some role in the future drug development.”
BUFFALO, NY- August 25, 2023 – A new editorial paper was published in Oncoscience (Volume 10) on August 17, 2023, entitled, “Cancer drug development yesterday, today and tomorrow.” In this new editorial, researchers Elzbieta Izbicka and Robert T. Streeper from New Frontier Labs discuss the history of cancer drug development and how it has evolved over time. The editorial also highlights the current state of cancer drug development and ...
2023-08-25
To discover how light interacts with molecules, the first step is to follow electron dynamics, which evolve at the attosecond timescale. The dynamics of this first step have been called charge migration (CM). CM plays a fundamental role in chemical reactions and biological functions associated with light–matter interaction. For years, visualizing CM at the natural timescale of electrons has been a formidable challenge in ultrafast science due to the ultrafine spatial (angstrom) and ultrafast temporal ...
2023-08-25
Younger atrial fibrillation (AFib) patients are most likely to benefit from more personalized, MRI-guided ablation treatments to correct irregular heart rhythms, according to a new artificial intelligence-guided analysis of results from the DECAAF II trial, one of the largest global studies of treatments for heart arrhythmias.
Tulane University researchers presented the findings at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam this week.
There’s been debate among physicians on whether going beyond traditional ablation treatments provides a benefit to patients. In 2021, the ...
2023-08-25
Sophia Antipolis, 25 August 2023: Competency-based cardiac imaging delivery is needed for effective and efficient patient care, according to a European Society of Cardiology (ESC) statement published today in European Heart Journal, a journal of the ESC.1
All seven ESC subspeciality associations have endorsed the document, namely the European Association of Cardiovascular Imaging (EACVI), Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Preventive Cardiology (EAPC), European Association ...
2023-08-25
Pregnant and recently postpartum women who suffer with mental health disorders may be vulnerable to using cannabis to self-medicate, according to a Rutgers-led study.
In a nationally representative survey, Qiana L. Brown, an assistant professor at the Rutgers School of Social Work, examined the relationship between mental health disorders, cannabis use and cannabis use disorder (CUD) among pregnant and postpartum women in the US. The findings were published online in advance of print in the July 2023 issue of the journal Drug and Alcohol Dependence.
“Before this study, we ...
2023-08-25
A study led by two University of Texas at Arlington public affairs professors, in partnership with city leaders, suggests downtown Arlington events would enjoy increased attendance if there were more parking, shaded areas and Instagram-ready photo opportunities.
Respondents to the survey consider downtown Arlington one of the top-three destinations in the city for entertainment.
“Downtown is competing with Texas Live! and The Highlands,” said Emily Nwakpuda, assistant professor in UTA’s College of Architecture, ...
2023-08-25
Freshwater ecosystems hold significant significance in the context of global biodiversity. These water bodies provide habitat for numerous plant and animal species, and they play a crucial role in maintaining food chains and preserving ecological balance. Mitigation measures including wastewater treatment and hydromorphological restoration have historically shown promise in improving environmental quality and supporting the recovery of freshwater biodiversity.
Together with a large international team the study’s first author, Prof. Dr. Peter Haase of the Senckenberg ...
2023-08-25
A powerful satellite called XRISM (X-ray Imaging and Spectroscopy Mission) is set to provide astronomers with a revolutionary look at the X-ray sky.
XRISM, led by JAXA (Japan Aerospace Exploration Agency) in collaboration with NASA and with contributions from ESA (European Space Agency), is scheduled to launch on an H-IIA rocket from Japan’s Tanegashima Space Center at 8:26 p.m. EDT on Sunday, Aug. 27 (9:26 a.m. on Monday, Aug. 28, in Japan). JAXA will stream the launch live ...
2023-08-25
Endometriosis is a chronic – often painful – illness that only affects women. New research shows potential for shortening the path to diagnosis and treatment. In the years prior to being diagnosed with endometriosis, women with the chronic illness have more contact than average with their GP, private gynaecologist and the hospital service.
Researchers analysed 129,696 Danish women's utilisation of the healthcare sector, with particular focus on the 21,616 women who were diagnosed with endometriosis between 2000 and 2017.
"We can see that ...
2023-08-25
In certain trees, soils can form along branches and can support varied plant and animal life. However, what conditions these ‘canopy soils’ form in, and what kind of biodiversity they support, has been difficult to study.
Now, researchers from Utah State University and Imperial College London have surveyed dozens of trees in Costa Rica, mapping the canopy soils to determine where they form and how they might be affected by a changing climate. The results are published in Geoderma.
First author Jessica Murray, from Utah State University, said: “We found canopy soils most often form in cool, foggy areas in these tropical forests ...
LAST 30 PRESS RELEASES:
[Press-News.org] Focused update of ESC Heart Failure Guidelines published today
